Crohn's disease medical therapy

Jump to navigation Jump to search

Crohn's disease

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Crohn's Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Crohn's disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Crohn's disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Crohn's disease medical therapy

CDC on Crohn's disease medical therapy

Crohn's disease medical therapy in the news

Blogs on Crohn's disease medical therapy

Directions to Hospitals Treating Crohn's disease

Risk calculators and risk factors for Crohn's disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overiew

Treatment options include medications, nutrition supplements, surgery, or a combination of these options. The goals of treatment are to control inflammation, correct nutritional deficiencies, and relieve symptoms like abdominal pain, diarrhea, and rectal bleeding. Treatment for Crohn’s disease depends on the location and severity of disease, complications, and the person’s response to previous medical treatments when treated for recurring symptoms. Some people have long periods of remission, sometimes years, when they are free of symptoms. However, the disease usually recurs at various times over a person’s lifetime.

Medical Therapy

The first step in the management of an acute Crohn's disease attack involves determining the anatomical extent of the disease endoscopically, and the severity of the disease, clinically. This classification is important to determine the necessity for topical (in distal disease) or systemic (in extensive disease) pharmacotherapy. Additionally, the severity of the disease may help determine the prognosis and the requirement for more aggressive intervention. Once the disease goes into remission, the goal of maintenance therapy is to prevent any subsequent acute exacerbations.

  • Standard treatment for Crohn's disease depends on extent of involvement and disease severity (e.g. mild, moderate, severe and fulminant) and can be discussed as follows:
  • 1. Mild to Moderate Crohn's Disease
    • Ileitis and colitis
      • Preferred regimen for illeitis and rt side colitis: Oral budesonide (9 mg/day)
      • Preferred regimen distal colitis : Topical mesalamine or topical steroids (enemas or suppositories)
      • Preferred regimen other site :Oral mesalamine (4 g/day) or oral sulfasalazine (3-6 g/day)
      • Alternative regimen (1): Mesalamine enemas or suppositories (in patients refractory to topical corticosteroids or oral aminosalicylates.
      • Alternate regimen (2): Oral prednisone up to 40-60 mg/day AND infliximab 5mg/kg at weeks 0, 2, 6 of treatment
        • Note: Effective dose of Sulfasalazine is 4-6g/day in 4 doses; mesalamine is 2-4.6g/day in 3 doses; balasalazine 6.75g/day in 3 doses; mesalamine multimatrix formulation is 2.4 to 4.8 g/day. These drugs are effective within 2.4 weeks.
    • Oral lesion
  • Gastroduodenal disease
    • Preferred regimen (1): PPI or H2 antagonist, or sucralfate
    • Preferred regimen (2): Oral mesalamine (Pentasa: 2 g/day)
  • Maintaince therapy
    • Preferred regimen for proctitis: Mesalamine suppositories
    • Preferred regimen for distal colitis : Mesalamine enemas
    • Preferred regimen for others: Oral sulfasalazine or olsalazine or mesalamine(3-3.6 g/day) or balsalazide
  • 2. Management of Moderate to Severe Crohn's Disease
    • Acute Management
      • Preferred regimen (1): Oral steroids (in patients refractory to aminosalicylates in combination with topical therapy)
      • Alternate regimen (2): Methotrexate (25 mg/wk i.m and once improvement 15 mg/wk i.m or oral or s.c) (in patients refractory to oral steroids)
      • Alternative regimen (3): infliximab 5mg/kg I.V. at weeks 0,2, and 6 (steroid refractory or steroid dependent despite adequate 6-MP dosing or intolerant to other regimens)
      • Alternative regimen (4): Adalimumab (160 mg s.c at 0 wk and 80 mg/2 wks)
      • Alternative regimen (5): Certolizumab pegol (400 mg/4wk s.c)
      • Alternative regimen (6): Azathioprine (2-3 mg/kg/day) OR 6-mercaptopurine (1-1.5 mg/kg/day)
        • Note (1): Infliximab is contraindicated in patients with untreated latent TB, pre-existing demyelinating disorder, optic neuritis, moderate to severe CHF, current or recent malignancy
        • Note (2): Transdermal nicotine is effective in achieving remission.
  • Maintenance of Remission
    • Preferred regimen (1): 6-mercaptopurine (1.5 mg/kg) OR azathioprine (2-2.5 mg/kg)
    • Alternate regimen (2): infliximab (in patients with successful induction with infliximab)
    • Alternate regimen (3): infliximab and azathioprine therapy
    • Alternate regimen (4): Methotrexate therapy (15 mg/wk i.m) (For methotrexate induced remissions)
    • Alternate regimen (5): Adalimumab therapy (40 mg/wk s.c): For adalimumab induced remissions
    • Alternate regimen (6): Certolizumab pegol therapy (400 mg/ 4wk s.c): For certolizumab pegol induced remissions
    • Alternate regimen (7): Natalizumab therapy (300 mg/ 4wk s.c): For natalizumab induced remissions
      • Note (1) : Corticosteroids are not recommended for long-term maintenance therapy
      • Note (2) : Monitor CBC every 3 months, monitor periodically for side effects
  • 3.Management of Severe to Fulminant Crohn's Disease
    • Acute Management
      • Preferred Regimen (1): Maximal oral treatment with prednisone AND oral aminosalicylate drugs AND topical mesalamine
      • Alternate regimen (2): Infliximab 5mg/kg (if refractory and urgent hospitalization is not necessary)
      • Alternate regimen (3): Intravenous corticosteroids (if patient presents with toxicity)

Pharmacotherapy

Aminosalicylates

Sulfasalazine has been a major agent in the therapy of mild to moderate UC for over 50 years. In 1977 Mastan S.Kalsi et al determined that 5-aminosalicyclic acid (5-ASA and mesalazine) was the therapeutically active compound in sulfasalazine. Since then many 5-ASA compounds have been developed with the aim of maintaining efficacy but reducing the common side effects associated with the sulfapyridine moiety in sulfasalazine.[1]

Corticosteroids

Immunosuppressive drugs

Biological treatment

Contraindicated medications

Crohn's disease is considered an absolute contraindication to the use of the following medications:

References

  1. S. Kane (2006). "Asacol - A Review Focusing on Ulcerative Colitis".

Template:WH Template:WS